Previous studies have reported conflicting results regarding the interaction between SGLT2 inhibitors and cancer risk: a slightly—not statistically significantly—elevated risk of bladder cancer in men and of breast cancer in women was initially reported; however, this has since been attributed to detection bias, as both animal studies using higher doses and better-powered human studies have not detected an increased risk of cancer in those treated with SGLT2 inhibitors [64]. Here, SLC5A2 is linked to urinary bladder carcinoma.